Spero Therapeutics ($SPRO) Stock Hub: Utebzi, SP001 and New Financing Capacity

01 Current research position

Utebzi is FDA-approved and partnered with GSK; SP001 targets a Phase 2 start in Q2 2027. The August 28 shelf and ATM add potential financing capacity, not cash already raised. September employee awards and the September 15 investor presentation are the latest corporate updates.

June cash excludes July transactions. Management guides to H2 2029 under its plan, a forward-looking estimate rather than guaranteed funding. No SP001 patient efficacy in IgG4-related disease has been demonstrated.

02 Investment summary and central debate

The central debate is whether Spero can create more value with SP001 and its retained Utebzi economics than it consumes through the Innovent license, clinical development and the royalty-backed capital structure. At the September 4 close of $1.21, basic equity value using August 7 SEC shares was approximately $70.46 million. That is small relative to the company’s stated liquidity, but a direct cash-versus-market-cap comparison is misleading: the July financing carries a 10% note claim, $35 million is payable upfront to Innovent, future operating burn remains, and most defined GSK proceeds are sold after note repayment.

03 How the SPRO thesis changed

04 Utebzi: approval is real, commercialization is the new test

The FDA approved Utebzi (tebipenem pivoxil hydrobromide) on June 17, 2026 as the first oral carbapenem therapy for adults with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral treatment options and whose infections are caused by specified susceptible microorganisms. The restricted population matters: this is not a broad first-line oral antibiotic label.

PIVOT-PO randomized hospitalized adults to oral Utebzi 600 mg every six hours or intravenous imipenem-cilastatin every six hours for seven to ten days. The FDA described comparable composite response in the 929-patient intention-to-treat population. Common adverse reactions included diarrhea, headache, nausea, abdominal pain and liver-enzyme elevations; Clostridioides difficile-associated diarrhea and carnitine-related precautions remain relevant.

05 GSK economics and the royalty-financing waterfall

GSK holds commercialization rights in the United States and Europe. The original agreement included $66 million upfront, up to $525 million of development, regulatory and commercial milestones and tiered royalties ranging from low-single digits to low-double digits. GSK expects U.S. availability by the end of 2026; that is partner guidance, not a guaranteed launch date.

In July 2026, Spero raised $105 million gross through non-recourse arrangements with healthcare royalty investors. The notes have a nine-year maturity and a 10% annual interest rate that may be capitalized when not paid. They are generally serviced from defined GSK proceeds. After repayment of the notes, purchasers are entitled to 65% of defined GSK proceeds and Spero retains 35%, subject to the transaction documents.

The financing includes limited-recourse guarantees and defined breach/default exceptions. Non-recourse does not mean no debt or economic cost. Notes accrue 10% annually, capitalized quarterly when unpaid from available proceeds, and mature nine years after closing. The 65%/35% allocation applies only after full note repayment.

SEC · Note 12

06 SP001: a Phase 2-ready anti-CD40L reset

SP001, previously IBI355, is a third-generation fully humanized, Fc-silent IgG1 monoclonal antibody targeting CD40 ligand. Spero licensed exclusive rights outside mainland China, Hong Kong, Macau and Taiwan. The Fc-silent design is intended to preserve CD40L pathway blockade while reducing platelet activation and thrombotic risk associated with first-generation antibodies; this is a mechanistic design rationale, not yet a clinical guarantee.

Innovent has completed two Phase 1 healthy-volunteer studies and a Phase 1b multiple-ascending-dose study in primary Sjögren’s syndrome. Spero plans to advance the asset first in IgG4-related disease. The agreement requires a U.S. IND filing within 12 months of July 8, 2026, subject to specified extensions.

The license requires a $35 million upfront payment, up to approximately $1.05 billion in development, regulatory and commercial milestones and high-single-digit to mid-teen royalties on net sales. These potential milestones are contingent obligations, not present debt or a forecast of payments.

07 What the human data do—and do not—show

The disclosed Phase 1b Sjögren’s study was double-blind and placebo-controlled, with three intravenous dose cohorts of 7.5, 15 and 30 mg/kg every four weeks for four doses. Each active cohort included eight patients; pooled placebo included six. Spero’s presentation reported no serious adverse events, linear pharmacokinetics, an approximately 28-day half-life, low anti-drug antibodies and exploratory improvements in ESSDAI, ESSPRI and autoantibodies.

Any cross-study comparison with other CD40L agents is weak because populations, endpoints, dosing and trial designs differ. The disclosed data justify a Phase 2 test; they do not establish efficacy or a best-in-class profile.

NCT06484855 reports 30 participants and completion July 25, 2025, primary completion June 21, last update September 15, 2025. These dates describe the earlier Sjögren’s study, not an IgG4-RD readout or proof of the planned U.S. Phase 2 starting.

08 Planned IgG4-RD Phase 2: the next value-creation test

Spero’s July presentation outlines an open-label 24-week study with an optional extension to week 52, two dose groups of approximately 15 patients each, steroid tapering and change in IgG4-RD Responder Index at week 24 as the primary endpoint. Eligible patients would have active disease and historical involvement of more than one organ.

The company targets trial initiation in the second quarter of 2027. This design is proposed, not yet registered or initiated. An open-label, roughly 30-patient study can produce a useful biological and clinical signal, but placebo effects, background steroid taper, organ heterogeneity and small subgroups will complicate interpretation. The quality of the IND, protocol, central adjudication and biomarker plan will matter as much as the headline enrollment date.

09 IgG4-related disease and the treatment benchmark

IgG4-related disease is a chronic fibro-inflammatory disorder that can affect the pancreas, salivary glands, kidneys, lungs, retroperitoneum and other organs. Organ damage and relapse risk create a need for steroid-sparing treatment. Spero cites an estimated 20,000–40,000 diagnosed U.S. patients; this is a company/third-party estimate and should not be treated as a verified addressable-market count.

Uplizna (inebilizumab, anti-CD19) became the first FDA-approved treatment for IgG4-RD in April 2025. In the pivotal study, Amgen reported an 87% reduction in flare risk versus placebo. That sets a meaningful efficacy benchmark and proves regulatory feasibility, but it does not validate SP001’s mechanism or commercial positioning.

10 Competitive landscape and pathway read-through

The relevant competition is broader than direct IgG4-RD programs. Uplizna is approved; obexelimab and rilzabrutinib are listed by Spero as Phase 3 competitors. Outside IgG4-RD, Sanofi’s frexalimab and Amgen’s dazodalibep provide read-through for CD40/CD40L pathway interest in multiple sclerosis and Sjögren’s disease. Pathway investment by larger companies supports biological relevance, not SP001-specific probability.

11 Legacy pipeline: no longer the valuation anchor

Spero ceased development of SPR206 in March 2025 and ceased development of SPR720 in November 2025; the latter followed earlier 2024 interim data from the Phase 2a program in non-tuberculous mycobacterial pulmonary disease. These assets may retain contractual or residual optionality, but current filings do not support treating them as active core value drivers.

The operating center of gravity is now SP001. Utebzi is a partnered commercial economic interest, not a product Spero will launch itself. Investors should therefore avoid blending the old anti-infective pipeline narrative with the new immunology thesis.

12 Second-quarter 2026 financial baseline

The historical revenue line is not a commercial-sales run rate. Future reported economics will depend on accounting for GSK milestones/royalties and the financing arrangements. At the same time, SP001 development will rebuild R&D spending from a temporarily low base.

Exact June cash was $50.774M. H1 operating cash flow was positive $10.509M, helped by the $25M GSK milestone received in February; it is not recurring commercial cash generation. H1 net loss was $16.755M. June cash + $105M July gross financing − $35M Innovent upfront obligation = $120.774M before discounts, fees and later spending: an illustrative bridge, not September reported cash. The H2 2029 runway already reflects planned transaction economics; do not subtract the upfront twice.

SEC · 10-Q

13 Capital structure, dilution and runway

Spero reported 58,234,827 common shares outstanding on August 7, 2026. At June 30 it also had approximately 3.57 million options outstanding at a weighted-average exercise price of $7.20 and about 4.17 million restricted stock units. The weighted-average option exercise price exceeds the current stock price; this does not establish that every option is out of the money; RSUs can dilute as they vest. A further 7.15 million shares were available under equity plans, but ungranted plan capacity is not the same as currently outstanding diluted shares.

Stockholders approved an increase in authorized common shares from 120 million to 240 million on June 23. Spero reported no 2026 sales under its at-the-market facility through the Q2 filing date. The larger authorization preserves financing flexibility and dilution capacity even though the July transaction did not issue common stock.

August 28: a new $300M universal shelf includes a $100M Jefferies ATM, not an additional $100M. The 8-K states registration was not effective at filing and sales could not occur before effectiveness. No subsequent effectiveness or ATM proceeds were verified in the filings reviewed. Commission can be up to 3%. These are potential securities sales, not $300M raised or cash to add to the July bridge.

The former $75M Cantor ATM terminated August 28 without penalties; that filing reports no 2024–2025 sales, while Q2 separately reports no 2026 sales through its reporting period. At the September 4 close of $1.21 and 58,234,827 common shares at August 7, basic equity value is approximately $70.46M. Potential awards and future issuance remain separate.

SEC · ATM · SEC · S-3

14 Governance, leadership and ownership

Esther Rajavelu is President and Chief Executive Officer and also signed the Q2 filing as Chief Financial Officer. Spero announced Debra Zack’s appointment as Chief Medical Officer in July 2026, strengthening clinical leadership ahead of the SP001 transition. The execution test is whether a lean organization can integrate an externally originated immunology asset, file an IND and start a rare-disease study on schedule.

GSK disclosed ownership of 9,190,606 shares, or 15.9% of shares outstanding as of the 2026 proxy record date, making it the only holder above 5% identified in that filing. This is strategic alignment, but Utebzi commercialization decisions remain under GSK’s control and its product-level incentives are not identical to Spero common shareholders’ interests.

September 3 disclosure: September 1 grants to new employees comprise 102,000 RSUs and 67,600 options with multiyear vesting. They are compensation awards, not open-market purchases or all immediately outstanding shares. The August 3 CMO grant separately comprised 162,311 RSUs and 324,675 options at $1.54.

IR · employee awards

The Q2 filing reports that the SEC concluded its company investigation and notified Spero January 20, 2026 that it did not intend to recommend enforcement against the company based on information then available. Separately, former executives settled January 16 without admitting or denying the findings except jurisdiction. The company investigation is not described here as a still-pending Wells Notice.

15 Valuation and market structure

Value separately cash after fees and burn, encumbered GSK proceeds, retained post-note participation and the early SP001 development option, less future spending. The $1.05B Innovent milestone ceiling is contingent consideration, not enterprise value. Do not add financing or shelf capacity to cash twice, or assign Spero the full unencumbered Utebzi stream.

StockTwits September 6: canonical sentiment 44/100, bearish; activity 49/100, normal; 2,846 watchers. Provider scores are not the percentage of all investors bullish or a clinical probability. Retail claims that shelf capacity is cash received or that royalty financing has no obligations contradict SEC terms.

16 Catalyst calendar and monitoring windows

Only the contractual IND deadline is hard-dated. Launch and trial timing are company or partner expectations and can move.

Confirmed next investor event: September 15 at 13:30 EDT / 19:30 Italy, H.C. Wainwright; a presentation, not a promised clinical readout. IgG4-RD Phase 2 initiation remains targeted for Q2 2027. The Innovent contract requires a U.S. IND within 12 months of July 8, 2026, subject to defined extensions; that deadline is not FDA clearance or first patient dosing.

IR · H.C. Wainwright · SEC · Innovent

17 Scenario framework: evidence before price targets

No target price is assigned. The timing and waterfall of GSK proceeds, financing accounting and an unregistered SP001 Phase 2 do not support false numerical precision.

18 Ranked risks and falsifiable checklist

• 1. Clinical translation: Sjögren’s exploratory data may not reproduce in IgG4-RD.
• 2. Capital structure: 10% note accrual and sale of 65% of defined post-note GSK proceeds can absorb asset value.
• 3. Commercial dependency: GSK controls launch execution, and the restricted label can limit uptake.
• 4. Timing: IND, trial registration and first-patient dosing can slip.
• 5. Safety: larger and longer studies may reveal immune or thrombotic risks not visible in the small dataset.
• 6. Dilution: equity awards, ATM capacity and 240M authorized shares preserve future dilution risk.
• 7. Competitive: Uplizna and later-stage programs may raise the efficacy and convenience bar.

19 Merlintrader SPRO coverage archive

This hub consolidates the full prior English-language SPRO coverage and supersedes its pre-approval framing. Older articles remain useful as a dated record of how the catalyst evolved.

20 Bottom line: funded reset, unproven new engine

Spero has materially improved its survival horizon. Utebzi approval converted a regulatory option into a partnered commercial asset, and July’s financing gave management time to build a new pipeline without immediately issuing common shares. The trade-off is that much of the future GSK stream is now claimed by the financing waterfall.

SP001 is the new upside engine, but it is still an early clinical asset entering a disease in which it has not generated patient data. The disciplined posture is proof-building watchlist: value the runway conservatively, avoid double counting Utebzi economics, and wait for launch evidence, IND clearance and a registered Phase 2.